Nivolumab-associated nausea and vomiting as an immune adverse event

Immunotherapy in the form of programmed cell death protein 1 (PD-1) inhibitors such as nivolumab have been found highly effective in treatment of several malignancies, including metastatic melanoma and squamous non-small-cell lung cancer [1,2]. Although studies suggest smaller percentages of immune-related adverse events (iAEs) with the use of PD-1 inhibitors as compared with cytotoxic T-lymphocyte–associated antigen 4 inhibitors, the increasingly wide use of these newer agents places importance on physician awareness and recognition of their side-effects [3].

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vQYwgY
via IFTTT